Several variables, including age, are known to influence anxiety. Previous exposure to the elevated-plus maze (EPM) is known to modify emotional behaviour as retesting in the EPM at a standard age of 3 months increases open-arm avoidance and attenuates the effects of anxiolytic drugs. This study analysed whether similar results are obtained when older animals are subjected to these experimental paradigms. Overall, increasing age was associated with more signs of anxiety. Additionally, we observed a paradoxical behaviour pattern in aged-subjects that were re-exposed to the EPM, with mid-aged and old rats failing to display open arm avoidance (OAA) in the second trial; this qualitative shift in emotional behaviour was not associated with decreased locomotion. An examination of how age influences responsiveness to anxiolytic drugs, with or without previous maze experience, was also conducted. Midazolam (0.5 and 1 mg/kg) proved anxiolytic in maize-naive young animals; in marked contrast, in older animals midazolam at 1 mg/kg resulted in sedation but not anxiolyis. One trial tolerance to midazolam was evident in animals of both ages that were subjected to a second EPM trial; the latter phenomenon was apparently accentuated in older animals as they do not show open arm avoidance upon re-exposure to the EPM. These data suggest that the age-associated 'resistance' to anxiolytic drugs might be related to a qualitative shift in emotional behaviour.
Introduction
The elevated-plus maze (EPM) is currently the most popular and reliable animal test to evaluate anxiety behaviour in rodents [21, 33] . It relies on the conflict of the natural aversion of rodents to open spaces with the drive to explore a new environment [42] and has been extensively validated [27, 32] ; in accordance, it has proven to be essential in the screening of new anxiolytic drugs [11] . There are several variables known to influence behaviour in EPM [33] ; briefly, they can be divided in those depending on the subject (e.g. specie, strain, gender and age) and those depending on environment (e.g. housing, prior handling or stress, lighting levels). Previous exposure to the maze is recognized as an important modi-fier of performance; indeed, retest of rodents in the EPM increases open arm avoidance (OAA) [2, 12, 16, 19, 23, [34] [35] [36] . This OAA effect seems to be progressive, starting around the second minute of trial 1 and may even increase with further retesting [22, 35] .
Prior maze experience is also known to reduce or even abolish the anxiolytic effects of drugs that bind to the GABA-A receptor complex such as benzodiazepines, ethanol or phenobarbital [3, 15, 17, 34] , as well as drugs that block NMDA/glycine-B receptor activity such as memantine [4] . This loss of anxiolytic effect of drugs in the trial 2 of the EPM, designated as "one trial tolerance" (OTT) [14] , has also been observed in other animal models of anxiety [20, 24, 30] . The phenomenon of OTT, which seems to be independent of the drug treatment on trial 1 or the material of the maze [14] , occurs with inter-test intervals ranging from 24 h to 2 weeks [14, 34] . Different hypotheses have been advanced to explain the effect of prior maze experience in the increase of OAA and the phenomenon of OTT such as locomotor habituation [12] , acquisition of a phobic avoidance of open arms [15, 34] or a qualitative shift in the emotional state during trial 2 [22] . Yet, the ethologic and biologic significance of the behavioural changes elicited by prior maze experience still remain unclear.
Changes in emotional behaviour represent one of the most important aspects of aging in both humans and rodents. Taking into account the altering behaviour patterns of rats with different ages in the EPM [6, 25] and the relevance of prior experiences in the process of avoidance learning we designed the present study to further characterise the effect of prior maze exposure on the increase of OAA and the OTT phenomenon in different stages of the rat adult lifetime.
Materials and methods

Animals
Male Wistar rats (Charles Rivers Laboratories, Barcelona, Spain), aged 2, 3, 12 and 18 months were used; the weights of animals aged between 2 and 3 months ranged between 200 and 350 g while the older animals weighed 500 and 750 g. Animals were housed in a room adjacent to the laboratory, in groups of four (cage size 60 cm × 40 cm × 20 cm), under standard laboratory conditions with an artificial light/dark cycle of 12/12 h (lights on at 8 a.m.), temperature of 22
• C and free access to food and water. Animals were taken to the test laboratory at least 1 h prior to testing and all experimental sessions were conducted during the diurnal phase, between 12:00 and 18:00 h. All procedures were carried out in accordance with European Union Directive 86/609/EEC and NIH guidelines on animal care and experimentation.
Apparatus
The EPM was made of black polypropylene (ENV-560; MedAssociates, VT, USA), consisted of two opposite open arms (50.8 cm × 10.2 cm) and two enclosed arms (50.8 cm × 10.2 cm × 40.6 cm) elevated 72.4 cm above the floor. The junction area between the four arms measured 10 cm × 10 cm. A raised edge (0.5 cm) on the open arms provided additional grip for the rats.
Procedures
The experimental room was lit by 40 W fluorescent lamps mounted above the maze so that all arms were equally illuminated (300 lx at the maze floor level). Rats were placed individually in the centre of the maze facing a closed arm and were allowed 5 min of free exploration. Behavioural parameters were recorded with the use of an infra-red photobeam system connected to a computer with specific software (MedPCIV, MedAssociates, VT, USA). After each trial, the maze was cleaned with a 10% ethanol solution.
Evaluation of the open arm avoidance effect
To evaluate the OAA effect, the 48 rats used were divided into four different age groups (n = 12) of 2, 3, 12 and 18 months respectively. The animals were submitted to two trials in the EPM, with an intertrial interval of 24 h.
One trial tolerance to midazolam
Among the 90 rats used to assess the OTT phenomenon to midazolam, 47 were maze-naive while 43 were pre-exposed to the EPM with an intertrial interval of 24 h without drug treatment (mazeexperienced). Both groups were subdivided in two different age groups (3 and 12 months). Within each group, animals were randomly allocated to different treatment conditions ((saline, n = 8; 0.5, n = 7 or 1, n = 7) mg/kg midazolam). The injection-test interval employed was 15 min. Midazolam (Roche, Switzerland) was dissolved shortly before use in a 0.9% saline solution (which, alone, served as a vehicle control). The solutions were administered intraperitoneally in a volume of 0.15 ml/100 g. 
Behavioural analysis
Statistics
In the evaluation of the open arm avoidance effect, data from both trials was analysed by two-factor (age group × trial) repeated measures analysis of variance (ANOVA). The one trial tolerance to midazolam was analysed by three-factor (age group × maze experience × drug) analysis of variance (ANOVA). Between-subjects effects were assessed by one-way analysis of variance (ANOVA). Differences between groups were then determined by a Tukey's honestly significant difference test (Tukey HSD) post hoc analysis. The results are expressed as group means ± standard error. Statistical significance was accepted for a probability level below 0.05.
Results
Evaluation of the open arm avoidance effect
As illustrated in Table 1 , the repeated measures analysis of variance (ANOVA) performed revealed significant effect In trial 1, a progressive reduction of the % of time spent in the open arms of the EPM was observed with increasing age of maze naive rats. In trial 2, maze-experienced rats revealed a progressive increase in this parameter with increasing age, except for the rats of 18 months (Fig. 1) .
The intertrial differences analysis, revealed a significant reduction in the % of time spent in the open arms in trial 2 in rats of 2 months (F ( For the % of open arm entries, the same behavioural pattern was observed, with a significant decrease in trial 2 in rats of 2 months (F (1,23) = 5.539, p = 0.026) and 3 months (F (1,23) = 8.777, p = 0.007) but an increase, although not statistically significant in rats of 12 and 18 months of age (Fig. 1) .
The one-way ANOVA performed revealed significant differences in the variation in % of time spent in open arms (T2-T1), between younger rats of 2 months and older rats of 12 months (p < 0.001) and 18 months (p = 0.001) and between rats of 3 and 12 months (p = 0.005). The variation in the % of open arm entries (T2-T1) was significantly different between younger rats of 2 months and 12 (p = 0.012) and 18 months (p = 0.043) old rats, as well as between rats of 3 and 12 months (p = 0.02).
In the risk assessment behaviour parameter, significant intertrial differences were found in animals aged 2 months (p < 0.001) and 18 months (p < 0.001); in both cases, there was an increase in risk assessment behaviour in the second trial. No significant intertrial differences were observed in the 3-and 12-month groups. Interestingly, there was a progressive decline with increasing age in this parameter in trial 1 (Fig. 2) .
As a measure of general locomotor activity, the number of entries in the closed arms failed to reveal any significant intertrial differences between age groups. However, a progressive decrease in this parameter was observed with increasing age, except for the second trial in the rats of 18 months (Fig. 2) . Table 2 illustrates the three-factor (age × drug × maze experience) analysis of variance (ANOVA) performed to assess the one trial tolerance to midazolam that revealed a significant main effect of age for all the parameters evaluated. A significant effect of maze experience was found for all the parameters evaluated except for the number of closed arm entries. The effect of drug was only significant for the number of closed arm entries and risk assessment behaviour. Furthermore, this analysis revealed significant interactions between age and drug for the % of open arm time, age and maze experience for all the parameters evaluated, drug and maze experience for all the parameters except risk assessment behaviour and between the three factors for the number of closed arm entries.
One trial tolerance to midazolam
In accordance with the results of the OAA evaluation, significant differences between maze naive and mazeexperienced rats were found within the saline treated groups of different age. Maze-experienced rats at 3 months of age re- As illustrated in Fig. 3 , in maze naive rats of 3 months, significant differences were found between the saline treated group and the midazolam (1 mg/kg) treated group that re- Concerning the number of closed arm entries (Fig. 3) , maze naive rats of 12 months treated with midazolam (1 mg/kg) revealed a significant lower locomotor activity compared with the saline (F (2,19) = 9.361, p = 0.002) and midazolam (0.5 mg/kg) treated group (F (2,19) = 9.361, p = 0.01). Maze-experienced rats of 12 months treated with midazolam (1 mg/kg) showed a lower locomotor activity compared with midazolam (0.5 mg/kg) treated group (F (2, 19) = 7.085, p = 0.0014) which revealed a higher locomotor activity compared with the saline treated group (F (2,19) = 7.085, p = 0.0013). In the age group of 3 months, significant differences in this parameter were exclusively found in maze-experienced rats in which the midazolam (0.5 mg/kg) treated group revealed higher scores compared to saline (F (2,22) = 7.167, p = 0.021) and midazolam (1 mg/kg) (F (2,22) = 7.167, p = 0.004) treated rats. In the risk assessment behaviour parameter, significant differences were confined to the maze-experienced rats of 3 months, in which the midazolam (0.5 mg/kg) treated group revealed a higher score compared with the saline (F (2,22) = 8.834, p = 0.01) and midazolam (1 mg/kg) (F (2, 22) = 8.834, p = 0.028) treated rats (Fig. 4) .
Discussion
Aging is a multifactorial process that leads to neurobehavioral declines, although at different rates. Changes in emotional behaviour, including increased anxiety behaviour, represent one of the most important aspects of aging. This is perfectly illustrated by the analysis of medical prescription in aged persons, which is characterised by a significant increase in the use of anxiolytic drugs [9] . In accordance with other studies in rodents [6, 25] , we observed in the first trial of the EPM a progressive decrease in the % of time spent in the open arms and locomotor activity with increasing age. Interestingly, the % of time spent in the open arm declined consistently from the younger (2-month-old) to the older (18-month-old) groups of animals tested; age-associated declines in open arm entries, another marker of anxiety, were less obvious.
Also in agreement with literature [2, 12, 16, 19, 23, 34] our results confirm that retesting young adults (2-and 3-monthold animals) in the EPM increases open arm avoidance, as shown by the significant decrease of the % of time and open arm entries in the second trial. Rather surprisingly, an opposite effect was observed in mid-age rats (12 months) and old The mechanisms underlying both OAA and OTT are far from completely understood. It has been hypothesized that fear cues, known to be rapidly acquired during trial 1, might trigger endocannabinoid activation on plus-maze trial 2 [37] . Of direct relevance to this line of argument is a recent report that re-exposure to learned fear cues selectively increases endocannabinoid levels in the basolateral amygdala [28] , an area of brain crucial for emotional behaviour. Endocannabinoid increases become further relevant, when considering that activation of presynaptic cannabinoid receptors inhibits neurotransmitter release in several areas of the brain [13, 39] reducing particularly the GABAergic neurotransmission in limbic regions [1, 7, 31, 38, 40, 43] a fact that might lead to increase basal anxiety relative to trial 1.
Because endocannabinoids are involved in learning and memory processes [8] , their implication in OAA becomes further supported by observations showing that drugs (e.g. scopolamine) interfering with learning acquisition can blunt the OTT phenomenon [5] . Given that age is characteristically associated with impairments in learning processes, including fear conditioning [26] , one might speculate that age-induced deficits in fear acquisition might be essential to the absence of avoidance to the open arm in re-exposures to the EPM. Furthermore, it has been recently shown that CB1 endocannabinoid receptor expression and activity is decreased with age in humans [29] .
Irrespective of the mechanisms underlying the open arm avoidance phenomenon and the age-associated differences herein described, analysis of data allows us to rule out locomotor habituation [12] as a key factor in its genesis. In fact, although aging was associated with decreased activity, comparison of closed-arm entries between trials did not reveal significant variation in general locomotion activity in any of the age groups studied.
Repeated measures analysis of variance confirmed a significant effect of age in risk assessment behaviour, with a progressive decrease of risk assessment behaviour with aging, in both trials. However, significant intertrial variations in this parameter were confined to the youngest (2-monthold) or oldest (18-month-old) groups, in which there was an increased risk assessment in re-exposure to the EPM. This observation demonstrates that both developing (immature) and senescent rats display a different exploratory strategy when re-exposed to an anxiety model, suggesting a curious age-associated quantitative shift in anxious behaviour in age extremes.
Administration of midazolam to young maze-naive rats produced an anxiolytic effect; as expected, the anxiolytic effects of midazolam were compromised in young mazeexperienced rats. Curiously, the age of the subject affected the response to these drugs, as in older animals similar doses of midazolam failed to produce significant anxiolytic effects, suggesting an increased "resistance" and/or reduced density of GABA-A receptors in aged-subjects. Furthermore, 1 mg/kg of midazolam produced sedation in older animals, a finding that is in agreement with previous observations that the behavioural effect of benzodiazepines in aged rats favours a sedative profile in detriment of their anxiolytic actions [43] .
Despite significant interactions between age, drug and maze experience, these factors influenced behaviour differently: while, age was the major determinant of the locomotion (closed arm entries) and risk assessment behaviour, previous maze experience had the greatest influence on anxiety behaviour (% of time in open arms and % of open arm entries). Interestingly the latter factor per se failed to influence the number of closed arm entries (locomotion). Importantly, when assessing the one trial tolerance phenomenon to midazolam in different ages it becomes clear that the latter is preserved independently of the age of the subject. Yet, comparisons of % of open arm time and entries between agematched maze-naive versus maze-experienced animals revealed significant differences only in younger subjects. The lack of significant differences of previous maze experience in older animals is due to the paradoxical open arm avoidance previously observed rather than to an altered profile in drug response in the second trial of the maze. In other words, the apparent effect of age in the tolerance to midazolam should not be ascribed to an altered response to the drug but instead to the altered behaviour pattern in the re-exposure to the maze observed in drug-free animals: while in young animals there was a significant avoidance to open arms, re-exposure of old saline treated rats to the EPM was associated with a preference to open arms.
The paradoxical effect of aging in open arm avoidance, as well as the shift towards a predominant sedative response to benzodiazepines in aged animals, illustrates a qualitative change in emotional behaviour with increasing age that might influence the efficacy of anxiolytic drugs in elder subjects. The present results suggest that alterations in GABA-A receptor activity during the lifespan [41, 44] may underlie resistance to conventional anxiolytic agents. Thus, improved treatment outcome in anxiety disorders in older subjects will benefit from the design of pharmacological agents that are customized to meet the challenges of an altered neurochemical substrate during aging.
